Established annual sales of antibiotics were about $50 billion globally in 2010. The majority of these sales were derived from generic products. However, within this market sphere, drug choices for the treatment of common non-responsive infections are becoming increasingly limited and expensive and, in some cases, nonexistent as the choices simply do not work against the superbug infections. Thus, the higher value relevant markets are for the patient groups who are suffering from incurable or highly recalcitrant infections. According to recent Active Bacterial Core Surveillance Reports from the US Centers for Disease Control (CDC) MRSA positive cases (antibiotic resistant) can be as high as 30% of patients who present at primary or emergency care facilities. Data from Europe are comparable. Given that Chelation Partners can deliver antibiotics with enhanced efficacy or can restore efficacy against resistant pathogens, we expect this higher value market will be open.